Obesity Surgery

, Volume 27, Issue 12, pp 3306–3313 | Cite as

Safety and Effectiveness of an Endoscopically Placed Duodenal-Jejunal Bypass Device (EndoBarrier®): Outcomes in 114 Patients

  • Patrice M. Forner
  • Timothy Ramacciotti
  • John E. Farey
  • Reginald V. LordEmail author
New Concept



The duodenal-jejunal bypass liner (DJBL) is an endoscopically placed device designed to achieve weight loss and improve glycemic control in obese patients. Previous studies report promising results but typically included small patient numbers and short follow-up. This study aims to determine the safety and effectiveness of the device.


Study design:

A series of all patients treated by the DJBL at our institutions.

Outcome measurements:

Weight loss, biochemical measures, complications.


Between July 2012 and March 2015, 114 consecutive patients were treated for a mean 51.1 weeks (standard deviation (SD) 19.9 weeks). Mean total body weight change from baseline was 12.0 kg (SD 8.5 kg, p < 0.001). Mean percent total body weight loss (%TWL) was 10.5% (SD 7.3%). Mean HbA1c was not significantly improved, but of 10 patients on insulin, 4 ceased insulin and 4 reduced insulin dosages. There was a significant decrease in hemoglobin and total cholesterol and a significant increase in serum alkaline phosphatase. Seventy-four percent of patients experienced at least one adverse event, some of them serious including 6 device obstructions, 5 gastrointestinal hemorrhages, 2 liver abscesses, and 1 acute pancreatitis. Seventy-four percent of patients experienced weight gain after removal with a mean 4.5 ± 6.1 kg (p < 0.0001) within the first 6 months after explantation.


The DJBL provides significant but highly variable weight loss. Glycemic control was variable. Most insulin-requiring T2DM patients ceased or reduced insulin. Most patients experience an adverse event and most regain significant weight after device removal. Major adverse events can occur, including the potentially life-threatening complications of hepatic abscess and gastrointestinal hemorrhage.


Obesity Bariatric Endoscopy Diabetes mellitus 


Author Contributions

Patrice M. Forner—study concept and design, acquisition of data, analysis and interpretation of data, drafting of manuscript, statistical analysis.

Timothy Ramacciotti—clinical care, study concept and design, acquisition of data, study supervision

John E. Farey—acquisition of data, manuscript revision.

Reginald V. Lord—device implantation and removal, clinical care, study concept and design, critical revision of manuscript, study supervision.

Compliance with Ethical Standards

Informed consent was obtained from all individual participants included in the study.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 196 countries over 25 years. New England Journal of Medicine 2017; 377:13–27Google Scholar
  2. 2.
    Mann T, Tomiyama AJ, Westling E, et al. Medicare’s search for effective obesity treatments: diets are not the answer. Am Psychol. 2007;62(3):220–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Colquitt JL, Picot J, Loveman E, et al. Surgery for obesity. The Cochrane database of systematic reviews. 2009;2:CD003641.Google Scholar
  4. 4.
    Braunwald E, Fahrbach K, Jensen MD, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.CrossRefPubMedGoogle Scholar
  5. 5.
    Bult MJF, van Dalen T, Muller AF. Surgical treatment of obesity. European journal of endocrinology / European Federation of Endocrine Societies. 2008;158(2):135–45. Scholar
  6. 6.
    SchauerPR,BhattDL,Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med 2014;370(21):2002–2013.Google Scholar
  7. 7.
    Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery. 2007;142(4):621–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Stenberg E, Szabo E, Ågren G, et al. Early complications after laparoscopic gastric bypass surgery: results from the Scandinavian Obesity Surgery Registry. Ann Surg. 2014;260(6):1040–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Consortium LAoBS. Peri-operative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009;361(5):445.Google Scholar
  10. 10.
    Topart P, Becouarn G, Ritz P. Comparative early outcomes of three laparoscopic bariatric procedures: sleeve gastrectomy, Roux-en-Y gastric bypass, and biliopancreatic diversion with duodenal switch. Surg Obes Relat Dis. 2012;8(3):250–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Kehagias I, Karamanakos SN, Argentou M, et al. Randomized clinical trial of laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for the management of patients with BMI< 50 kg/m2. Obes Surg. 2011;21(11):1650–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Tarnoff M, Rodriguez L, Escalona A, et al. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc. 2009;23(3):650–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Gersin KS. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976–82.CrossRefPubMedGoogle Scholar
  14. 14.
    Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236–43.CrossRefPubMedGoogle Scholar
  15. 15.
    Health UDo, Services H. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2013.Google Scholar
  16. 16.
    Escalona A, Pimentel F, Sharp A, et al. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg. 2012;255(6):1080.CrossRefPubMedGoogle Scholar
  17. 17.
    Koehestanie P, de Jonge C, Berends FJ, et al. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Muñoz R, Dominguez A, Muñoz F, et al. Baseline glycated hemoglobin levels are associated with duodenal-jejunal bypass liner-induced weight loss in obese patients. Surg Endosc. 2014;28(4):1056–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Rodriguez-Grunert L, Neto MPG, Alamo M, et al. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis. 2008;4(1):55–9.CrossRefPubMedGoogle Scholar
  20. 20.
    de Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg. 2013;23(9):1354.CrossRefPubMedGoogle Scholar
  21. 21.
    Betzel B, Koehestanie P, Aarts EO, et al. Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity. Gastrointest Endosc. 2015;82(5):845.CrossRefPubMedGoogle Scholar
  22. 22.
    Sarzynski E, Puttarajappa C, Xie Y, et al. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci. 2011;56(8):2349–53.CrossRefPubMedGoogle Scholar
  23. 23.
    De Moura EGH, Orso IRB, da Costa MB, et al. Improvement of insulin resistance and reduction of cardiovascular risk among obese patients with type 2 diabetes with the duodenojejunal bypass liner. Obes Surg. 2011;21(7):941–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Rodriguez L, Reyes E, Fagalde P, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009;11(11):725–32.CrossRefPubMedGoogle Scholar
  25. 25.
    de Moura EGH, Martins BC, Lopes GS, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther. 2012;14(2):183.CrossRefPubMedGoogle Scholar
  26. 26.
    Cohen RV, Neto MG, Correa JL, et al. A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism. 2013;98(2):E279–E82.CrossRefGoogle Scholar
  27. 27.
    Abu Dayyeh BK, Kumar N, Edmundowicz SA, Jonnalagadda S, Larsen M, Sullivan S, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointestinal endoscopy. 2015;82(3):425–38.e5.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Patrice M. Forner
    • 1
  • Timothy Ramacciotti
    • 2
    • 3
  • John E. Farey
    • 1
  • Reginald V. Lord
    • 2
    • 3
    Email author
  1. 1.St. Vincent’s Centre for Applied Medical ResearchSydneyAustralia
  2. 2.St. Vincent’s Centre for Applied Medical Research and University of New South WalesSydneyAustralia
  3. 3.Department of Surgery, School of MedicineUniversity of Notre DameSydneyAustralia

Personalised recommendations